Press Releases

Hero overlay Cancer research Analyst Coverage Annual Report Proxy Materials Corporate Governance Events Presentations Financial Information Investor Disclaimer Press Releases Stock Information
MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.
May 4, 2022
Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality,
April 21, 2022
MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time. The call will be webcast live and may be accessed at
April 20, 2022
Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region Also Announces First Commercial Services Provider in Europe MENLO PARK, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly
March 23, 2022
MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of
February 25, 2022

Investor Contact

Pacific Biosciences of California, Inc.
1305 O’Brien Drive, Menlo Park, CA 94025
ir@pacb.com